Top Pharmaceutical Companies in Mumbai (42)
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high...
Zeno Health is Mumbai's #1 Generic Medicine focussed pharmacy with a widespread footprint in Mumbai and Pune with 175+ stores. Founded in 2017 by IIT Bombay alumni- Siddharth Gadia and Girish Agarwal, with a vision to create a new world of holistic healthcare that is authentic, accessible and affordable to all. Zeno Health offers genuine, high-quality generic & branded medicines...
"Novapure Healthcare Pvt. Ltd. is a leading provider of comprehensive solutions in the biomedical sector, specializing in complex organic small molecules. We are recognized as a prominent manufacturer and supplier of Impurity standards and Specialty chemicals. Our meticulously crafted product portfolio is designed to meet the specific demands of custom synthesis, formulation development, and analytical development processes within the pharmaceutical...
Hetero Healthcare Ltd is a leading Innovative Pharmaceutical Company in India, headquartered at Hyderabad. We aim to improve the quality life of the people with our product line and along with a continuous Research and Development process. Our team is more committed, to finding tomorrow’s cures and treatments for some of the most serious diseases. We believe that new medicines...
Medikabazaar is a leading healthcare solutions provider, revolutionizing the way medical supplies are procured. With our cutting-edge e-commerce platform, we empower healthcare institutions, clinics, and individual practitioners to streamline their purchasing processes, saving time and resources. At Medikabazaar, we understand the unique challenges faced by the healthcare industry, and we are committed to delivering innovative solutions. Our extensive catalog offers...
Titan is a speciality pharmaceutical & generic formulation company engaged in developing & manufacturing Sustained & Modified Release Pellets, DC Granules, & Taste Masked Granules.
Hear now. And always As the global leader in implantable hearing solutions, at Cochlear (ASX: COH) we are committed to our mission to help people hear and be heard. Our story started more than four decades ago when Professor Graeme Clark pioneered the world's first multi-channel cochlear implant and created an entirely new treatment for hearing loss. Since our formation...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
AstraZeneca's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.
Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.
Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.
Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It...
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions...
Procter & Gamble Company is an American multi-national consumer goods corporation. P&G was founded over 180 years ago as a soap and candle company. Today, we’re the world’s largest consumer goods company and home to iconic, trusted brands, including Always®, Charmin®, Braun®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Oral B®, Pantene®, Pampers®, Tide®, and Vicks®. The design, development, growth and...
Procter & Gamble's Top Stability & Growth Strengths
Strong Market Position & Advantage: P&G is consistently characterized as the clear industry leader with dominant positions across core categories, anchored by flagship brands like Tide, Pampers, Gillette, Crest, and Oral‑B. Multiple sources in the provided materials frame it as leading peers across home care, baby/feminine, grooming, and oral care.
Innovation-Driven Growth: The company is repeatedly recognized for leadership in product innovation and is advancing new formats and data‑driven operations to sustain momentum. References cite top‑ranked innovation in household products for multiple consecutive years and highlight launches such as new detergent formats.
Resilient & Sustainable Growth: Recent updates indicate a return to positive unit volumes with modest organic sales and EPS increases, alongside reaffirmed low single‑digit growth guidance. Dividend increases and ongoing cash returns are emphasized as continuing, underscoring a steady, durable profile.
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon,...
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory,...
We’re an innovative and forward-thinking Commercial Pharma analytics startup based in the UK. Since 2014 we’ve been focusing our efforts on providing cutting edge input to pharmaceutical organisations throughout Europe and North America. By combining years of experience in healthcare, pharmaceutical and data , we provide a powerful tool for acquiring real actionable insights to Commercial strategy, Formulary status, Salesforce...
Bharat Serums and Vaccines Limited (BSV), a subsidiary of Mankind Pharma Limited, is one of the fastest growing biopharmaceutical company in India. For 50 years now, BSV has used its scientific resources to develop a range of biological, biotech and pharmaceutical products. Today, as we influence patient outcomes in the therapeutic areas of Women’s health and Critical Care and IUI-IVF, we...
Piramal Group is an Indian multinational conglomerate with a presence across healthcare, life sciences, drug discovery, financial services, alternative investment, and real estate.
Omya is a leading global producer of industrial minerals, primarily fillers and pigments derived from calcium carbonate and dolomite, and a worldwide distributor of specialty materials. The company operates across diverse sectors, including construction, polymers, pulp and paper, agriculture, and life sciences. It provides high-purity minerals and specialty ingredients designed to improve process efficiency and performance for customers in over...
